|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Pmv Pharmaceuticals, Inc. (PMVP) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
54,394,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile PMV Pharmaceuticals is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. p53 is a well-defined tumor suppressor protein known as the “guardian of the genome,” and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. Co.'s lead product candidate, PC14586, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
87,786 |
98,181 |
124,434 |
| Total Sell Value |
$0 |
$195,763 |
$264,577 |
$682,787 |
| Total People Sold |
0 |
1 |
3 |
3 |
| Total Sell Transactions |
0 |
1 |
3 |
4 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jalota Deepika |
Chief Development Officer |
• – – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
95,555 |
125,501 |
|
- |
|
| Mack David Henry |
President and CEO |
• • – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
163,890 |
442,460 |
|
- |
|
| Carulli Michael |
Chief Financial Officer |
• – – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
82,220 |
91,286 |
|
- |
|
| Carulli Michael |
Chief Financial OfficerOfficer |
• – – |
2024-01-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,066 |
|
- |
|
| Orbimed Genesis Gp Llc |
10% Owner |
– – • |
2023-11-22 |
4 |
S |
$2.23 |
$195,763 |
I/I |
(87,786) |
0 |
|
- |
|
| Mack David Henry |
President and CEO |
• • – |
2023-11-10 |
4 |
GA |
$0.00 |
$0 |
I/I |
85,307 |
165,307 |
|
- |
|
| Mack David Henry |
President and CEO |
• • – |
2023-11-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
85,307 |
278,570 |
|
- |
|
| Mack David Henry |
President and CEO |
• • – |
2023-10-18 |
4 |
OE |
$0.53 |
$105,156 |
D/D |
198,407 |
363,877 |
|
- |
|
| Jalota Deepika |
Chief Development Officer |
• – – |
2023-09-15 |
4 |
S |
$6.62 |
$27,168 |
D/D |
(4,104) |
29,946 |
|
- |
|
| Alland Leila |
Chief Medical Officer |
• – – |
2023-09-15 |
4 |
S |
$6.62 |
$41,646 |
D/D |
(6,291) |
45,909 |
|
- |
|
| Mack David Henry |
President and CEO |
• • – |
2023-08-07 |
4 |
OE |
$0.53 |
$45,315 |
D/D |
85,500 |
165,470 |
|
- |
|
| Kung Winston |
COO, CFO |
• – – |
2022-11-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,560 |
10,600 |
|
- |
|
| Jalota Deepika |
SVP, Regulatory Affairs and QA |
• – – |
2022-09-09 |
4 |
A |
$0.00 |
$0 |
D/D |
34,050 |
34,050 |
|
- |
|
| Alland Leila |
Chief Medical Officer |
• – – |
2022-09-09 |
4 |
A |
$0.00 |
$0 |
D/D |
52,200 |
52,200 |
|
- |
|
| Orbimed Genesis Gp Llc |
10% Owner |
– – • |
2022-05-26 |
4 |
S |
$15.93 |
$418,210 |
I/I |
(26,253) |
87,786 |
|
- |
|
| Mack David Henry |
President and CEO |
• • – |
2022-04-27 |
4 |
OE |
$0.53 |
$17,490 |
D/D |
33,000 |
79,970 |
|
- |
|
| Kung Winston |
COO, CFO |
• – – |
2022-04-20 |
4 |
OE |
$3.22 |
$12,880 |
D/D |
4,000 |
10,600 |
|
- |
|
| Orbimed Capital Llc |
10% Owner |
– – • |
2022-03-31 |
4 |
S |
$21.17 |
$730,365 |
I/I |
(34,500) |
0 |
|
- |
|
| Orbimed Capital Llc |
10% Owner |
– – • |
2022-03-30 |
4 |
S |
$22.39 |
$1,679,250 |
I/I |
(75,000) |
34,500 |
|
- |
|
| Orbimed Capital Llc |
10% Owner |
– – • |
2022-03-29 |
4 |
S |
$21.52 |
$7,854,800 |
I/I |
(365,000) |
109,500 |
|
- |
|
| Mack David Henry |
President and CEO |
• • – |
2022-03-08 |
4 |
OE |
$1.37 |
$27,400 |
D/D |
20,000 |
46,970 |
|
- |
|
| Kung Winston |
COO, CFO |
• – – |
2021-12-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,725 |
6,600 |
|
- |
|
| Mack David Henry |
President and CEO |
• • – |
2021-12-15 |
4 |
OE |
$0.53 |
$4,770 |
D/D |
9,000 |
26,970 |
|
- |
|
| Mack David Henry |
President and CEO |
• • – |
2021-12-09 |
4 |
GA |
$0.00 |
$0 |
I/I |
40,000 |
40,000 |
|
- |
|
| Mack David Henry |
President and CEO |
• • – |
2021-12-09 |
4 |
GD |
$0.00 |
$0 |
I/I |
40,000 |
187,915 |
|
- |
|
175 Records found
|
|
Page 1 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
